Regulation of signaling pathways by metal and metal-doped nanozymes in inflammatory bowel disease: A therapeutic perspective
Bibliographic record
Abstract
No abstract is available for this record. The assistant can identify its topic from the title, but cannot infer the study’s results.
Source: Not provided · Quality: missing
Research context
OpenAlex topics: Advanced Nanomaterials in Catalysis · Nanocluster Synthesis and Applications · Nanoplatforms for cancer theranostics
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (100+)
Show source-provided references
1. Strategies for targeting cytokines in inflammatory bowel disease10.1038/s41577-024-01008-6 ↗
2. N4BP3 facilitates NOD2-MAPK/NF-κB pathway in inflammatory bowel disease through mediating K63-linked RIPK2 ubiquitination10.1038/s41420-024-02213-x ↗
3. Biosynthetic enzyme analysis identifies a protective role for TLR4-acting gut microbial sulfonolipids in inflammatory bowel disease10.1038/s41467-024-53670-y ↗
4. Regulatory role of short-chain fatty acids in inflammatory bowel disease10.1186/s12964-022-00869-5 ↗
5. Anion-dependent layered double hydroxide nanoparticles regulate differentiation of CD206 + CX3CR1 + macrophages by inhibiting the IL-17 signaling pathway contributing to inflammatory bowel disease10.1002/adfm.202305042 ↗
6. Ulcerative colitis10.1016/S0140-6736(23)00966-2 ↗
7. Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care10.1016/S0140-6736(24)00983-8 ↗
8. Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier10.1186/s12967-024-05168-w ↗
9. Protective effect of salvianolic acid B in acetic acid-induced experimental colitis in a mouse model10.3390/pr9091589 ↗
10. Identification and multimodal characterization of a specialized epithelial cell type associated with Crohn’s disease10.1038/s41467-024-51580-7 ↗
11. Acute severe ulcerative colitis is associated with an increased risk of acute pouchitis10.1093/ibd/izad039 ↗
12. Inflammatory bowel disease and risk of adenocarcinoma and neuroendocrine tumors in the small bowel10.1016/j.annonc.2022.02.226 ↗
13. Protective effect of zinc oxide nanoparticles synthesized using Cassia alata for DSS-induced ulcerative colitis in mice model10.1007/s00449-024-03047-8 ↗
14. A lncRNA from an inflammatory bowel disease risk locus maintains intestinal host-commensal homeostasis10.1038/s41422-023-00790-7 ↗
15. Incidence, prevalence, and racial and ethnic distribution of inflammatory bowel disease in the United States10.1053/j.gastro.2023.07.003 ↗
16. Comparative Effectiveness of Upadacitinib and Tofacitinib in Inducing Remission in Ulcerative Colitis: Real-World Data10.1016/j.cgh.2023.03.040 ↗
17. Two-birds-one-stone” colon-targeted nanomedicine treats ulcerative colitis via remodeling immune microenvironment and anti-fibrosis10.1186/s12951-022-01598-0 ↗
18. Improved colonic inflammation by nervonic acid via inhibition of NF-κB signaling pathway of DSS-induced colitis mice10.1016/j.phymed.2023.154702 ↗
19. Chlorogenic acid supplementation alleviates dextran sulfate sodium (DSS)-induced colitis via inhibiting inflammatory responses and oxidative stress, improving gut barrier integrity and Nrf-2/HO-1 pathway10.1016/j.jff.2021.104808 ↗
20. TIPE-2 ameliorates inflammatory bowel disease in mice via inhibiting STAT3 and NF-kB activation10.1016/j.imlet.2023.02.005 ↗
21. Bergenin alleviates ulcerative colitis by decreasing gut commensal Bacteroides vulgatus -mediated elevated branched-chain amino acids10.1021/acs.jafc.3c09448 ↗
22. NEK7 interacts with NLRP3 to modulate the pyroptosis in inflammatory bowel disease via NF-κB signaling10.1038/s41419-019-2157-1 ↗
23. Alteration of miR-21, miR-433 and miR-590 tissue expression related to the TGF-β signaling pathway in ulcerative colitis patients10.1080/13813455.2020.1762656 ↗
24. Notch and TNF-α signaling promote cytoplasmic accumulation of OLFM4 in intestinal epithelium cells and exhibit a cell protective role in the inflamed mucosa of IBD patients
25. Mucosal host-microbe interactions associate with clinical phenotypes in inflammatory bowel disease10.1038/s41467-024-45855-2 ↗
26. Biocompatible carbon dots nanozymes as ROS/RNS modulators for ulcerative colitis alleviation by comprehensively orchestrating intestinal homeostasis
27. Restoration of dysregulated intestinal barrier and inflammatory regulation through synergistically ameliorating hypoxia and scavenging reactive oxygen species using ceria nanozymes in ulcerative colitis10.1186/s40824-023-00412-8 ↗
28. An orally administered gold nanocluster with ROS scavenging for inflammatory bowel disease treatment10.1016/j.fmre.2022.07.002 ↗
29. A new therapy against ulcerative colitis via the intestine and brain using the Si-based agent10.1038/s41598-022-13655-7 ↗
30. Quercetin alleviates intestinal oxidative damage induced by H 2 O 2 via modulation of GSH: in vitro screening and in vivo evaluation in a colitis model of mice10.1021/acsomega.0c00804 ↗
31. Oxidative stress and redox-modulating therapeutics in inflammatory bowel disease10.1016/j.molmed.2020.06.006 ↗
32. 2D nanozymes modulate gut microbiota and T-cell differentiation for inflammatory bowel disease management10.1002/adhm.202302576 ↗
33. Epithelial-immune cell crosstalk for intestinal barrier homeostasis10.1002/eji.202350631 ↗
34. Inflammation and aging: signaling pathways and intervention therapies10.1038/s41392-023-01502-8 ↗
35. Tailoring polymeric nanocarriers for hypoxia-specific drug release: insights into design and applications in clinics
36. Long-term exposure to air pollution and risk of incident inflammatory bowel disease among middle and old aged adults10.1016/j.ecoenv.2022.113835 ↗
37. Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy10.1186/s12951-023-02227-0 ↗
38. Inflammation status modulates the effect of host genetic variation on intestinal gene expression in inflammatory bowel disease10.1038/s41467-021-21458-z ↗
39. 5-Aminosalicylic acid alters the gut microbiota and altered microbiota transmitted vertically to offspring have protective effects against colitis10.1038/s41598-023-39491-x ↗
40. Enzyme-like biomimetic oral-agent enabling modulating gut microbiota and restoring redox homeostasis to treat inflammatory bowel disease
41. The emergence of inflammatory microglia during gut inflammation is not affected by FFAR2 expression in intestinal epithelial cells or peripheral myeloid cells10.1016/j.bbi.2024.03.016 ↗
42. ROS-responsive nanoparticles for oral delivery of luteolin and targeted therapy of ulcerative colitis by regulating pathological microenvironment
43. Selective tyrosine kinase 2 inhibitors in inflammatory bowel disease10.1016/j.tips.2022.02.008 ↗
44. Mend your fences10.1016/j.jcmgh.2017.03.007 ↗
45. Signaling pathways in intestinal homeostasis and colorectal cancer: KRAS at centre stage10.1186/s12964-021-00712-3 ↗
46. Innate lymphoid cells in intestinal homeostasis and inflammatory bowel disease10.3390/ijms22147618 ↗
47. Inflammatory Bowel Diseases (IBD) and the microbiome—searching the crime scene for clues10.1053/j.gastro.2020.09.056 ↗
48. Th17 cells at the crossroads of innate and adaptive immunity against infectious diseases at the mucosa10.1038/mi.2009.100 ↗
49. Curcumin ameliorates DSS‑induced colitis in mice by regulating the Treg/Th17 signaling pathway10.3892/mmr.2020.11672 ↗
50. Regulation of treg cells by cytokine signaling and co-stimulatory molecules10.3389/fimmu.2024.1387975 ↗
51. Activation and suppression of group 3 innate lymphoid cells in the gut10.1016/j.it.2020.06.009 ↗
52. Molecular mechanisms that influence the macrophage M1–M2 polarization balance10.3389/fimmu.2014.00614 ↗
53. Macrophage polarization in inflammatory bowel disease10.1186/s12964-023-01386-9 ↗
54. Cytokine networks and t-cell subsets in inflammatory bowel diseases10.1097/MIB.0000000000000714 ↗
55. The emerging role of oxidative stress in inflammatory bowel disease10.3389/fendo.2024.1390351 ↗
56. Design of diselenide-bridged hyaluronic acid nano-antioxidant for efficient ROS scavenging to relieve colitis10.1021/acsnano.2c05558 ↗
57. The Role of Reactive Oxygen Species (ROS) in the biological activities of metallic nanoparticles10.3390/ijms18010120 ↗
58. Designing nanozymes for in vivo applications10.1038/s44222-024-00205-1 ↗
59. A conserved mitochondrial ATP-binding cassette transporter exports glutathione polysulfide for cytosolic metal cofactor assembly10.1074/jbc.M114.553438 ↗
60. Crohn’s disease pathobiont adherent-invasive E coli disrupts epithelial mitochondrial networks with implications for gut permeability10.1016/j.jcmgh.2020.09.013 ↗
61. Antioxidant nanozymes as next-generation therapeutics to free radical-mediated inflammatory diseases: a comprehensive review10.1016/j.ijbiomac.2024.129374 ↗
62. Nanozyme enabled protective therapy for neurological diseases10.1016/j.nantod.2023.102142 ↗
63. Nanozyme-based cancer theranostics: a scientometric analysis and comprehensive review10.1016/j.nantod.2024.102386 ↗
64. Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy10.1016/j.actbio.2024.09.007 ↗
65. Inflammatory responses and inflammation-associated diseases in organs10.18632/oncotarget.23208 ↗
66. Peroxynitrite-activated fluorescent probe with two reaction triggers for pathological diagnosis and therapeutic evaluation of inflammation10.1016/j.bioorg.2024.107362 ↗
67. Mn 3 O 4 nanozyme loaded thermosensitive PDLLA-PEG-PDLLA hydrogels for the treatment of inflammatory bowel disease10.1021/acsami.3c03332 ↗
68. Hypoxia-tropic delivery of nanozymes targeting transferrin receptor 1 for nasopharyngeal carcinoma radiotherapy sensitization10.1038/s41467-025-56134-z ↗
69. Self-oxygenated biomimetic nanozyme for tumor catalytic immunotherapy
70. Mn 3 O 4 nanozyme for inflammatory bowel disease therapy
71. Integrated cascade nanozyme catalyzes in vivo ROS scavenging for anti-inflammatory therapy
72. Peroxidase-mimicking activity of nanozymes-loaded polymeric artificial organelles potentially active in acidic environment10.1002/pol.20230100 ↗
73. Transition-metal-based nanozymes for biosensing and catalytic tumor therapy10.1007/s00216-024-05345-2 ↗
74. Biomimetic copper single-atom nanozyme system for self-enhanced nanocatalytic tumor therapy10.1007/s12274-022-4359-6 ↗
75. AuPt alloy nanostructures with tunable composition and enzyme-like activities for colorimetric detection of bisulfide10.1038/srep40103 ↗
76. Functional nanomaterials with unique enzyme-like characteristics for sensing applications10.1039/C8TB02878H ↗
77. Nanomaterials with enzyme-like characteristics (nanozymes): next-generation artificial enzymes (II)10.1039/C8CS00457A ↗
78. Mechanism of pH-switchable peroxidase and catalase-like activities of gold, silver, platinum and palladium10.1016/j.biomaterials.2015.01.012 ↗
79. A curcumin-modified coordination polymers with ROS scavenging and macrophage phenotype regulating properties for efficient ulcerative colitis treatment10.1002/advs.202300601 ↗
80. An oral nano-antioxidant for targeted treatment of inflammatory bowel disease by regulating macrophage polarization and inhibiting ferroptosis of intestinal cells10.1016/j.cej.2023.142940 ↗
81. An orally administered CeO 2 @Montmorillonite nanozyme targets inflammation for inflammatory bowel disease therapy10.1002/adfm.202004692 ↗
82. Zero-valence selenium-enriched prussian blue nanozymes reconstruct intestinal barrier against inflammatory bowel disease via inhibiting ferroptosis and T cells differentiation10.1002/adhm.202203160 ↗
83. Orally administration of cerium oxide nanozyme for computed tomography imaging and anti-inflammatory/anti-fibrotic therapy of inflammatory bowel disease10.1186/s12951-023-01770-0 ↗
84. A valence-engineered self-cascading antioxidant nanozyme for the therapy of inflammatory bowel disease
85. Cu,Zn,I-Doped carbon dots with boosted triple antioxidant nanozyme activity for treatment of DSS-induced colitis10.1021/acsami.4c03627 ↗
86. Macrophage-biomimetic liposomes delivery of carbon dots nanozymes ameliorate ulcerative colitis by modulating inflammation pathways and remodeling the redox microenvironment10.1016/j.cej.2023.146796 ↗
87. Versatile carbon dots with superoxide dismutase-like nanozyme activity and red fluorescence for inflammatory bowel disease therapeutics10.1016/j.carbon.2023.01.006 ↗
88. A review on metal- and metal oxide-based nanozymes: properties, mechanisms, and applications10.1007/s40820-021-00674-8 ↗
89. Bioinspired design of Fe 3+ -doped mesoporous carbon nanospheres for enhanced nanozyme activity10.1002/chem.201801010 ↗
90. Modulating the coordination environment of carbon-dot-supported Fe single-atom nanozymes for enhanced tumor therapy
91. The emerging role of ferroptosis in intestinal disease10.1038/s41419-021-03559-1 ↗
92. Engineered procyanidin-Fe nanoparticle alleviates intestinal inflammation through scavenging ROS and altering gut microbiome in colitis mice10.3389/fchem.2023.1089775 ↗
93. Inflammation-free electrochemical in vivo sensing of dopamine with atomic-level engineered antioxidative single-atom catalyst10.1038/s41467-024-52279-5 ↗
94. One-Pot Synthesis of Fe/N-doped hollow carbon nanospheres with multienzyme mimic activities against inflammation10.1021/acsabm.9b01079 ↗
95. Artificial-enzymes-armed Bifidobacterium longum probiotics for alleviating intestinal inflammation and microbiota dysbiosis10.1038/s41565-023-01346-x ↗
96. Nanozyme-mediated catalytic nanotherapy for inflammatory bowel disease10.7150/thno.33727 ↗
97. Carbon dots-supported Zn single atom nanozymes for the catalytic therapy of diabetic wounds10.1016/j.actbio.2024.07.045 ↗
98. Carbon-based nanozymes: how structure affects performance10.26599/NBE.2024.9290053 ↗
99. Cu,Zn dopants boost electron transfer of carbon dots for antioxidation
100. Ultrasmall antioxidant cerium oxide nanoparticles for regulation of acute inflammation10.1021/acsami.1c16126 ↗